Lassa fever future or investigational therapies: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Lassa fever}} | {{Lassa fever}} | ||
{{CMG}} | |||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
==Overview== | |||
Researchers at the [[USAMRIID]] facility, where military biologists study infectious diseases, have a promising vaccine candidate. They have developed a [[Virus#Replication|replication]]-competent [[vaccine]] against Lassa virus based on recombinant vesicular [[stomatitis]] [[Vesicular stomatitis virus|virus]] vectors expressing the Lassa virus [[glycoprotein]]. After a single [[Intramuscular|intramuscular injection]], test primates have survived lethal challenge, while showing no clinical symptoms.<ref>{{cite journal |author=Geisbert TW, Jones S, Fritz EA, ''et al'' |title=Development of a new vaccine for the prevention of Lassa fever |journal=PLoS Med. |volume=2 |issue=6 |pages=e183 |year=2005 |pmid=15971954 |doi=10.1371/journal.pmed.0020183}}</ref> | |||
==References== | ==References== | ||
Revision as of 19:56, 20 December 2012
|
Lassa fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Lassa fever future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Lassa fever future or investigational therapies |
|
Risk calculators and risk factors for Lassa fever future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Researchers at the USAMRIID facility, where military biologists study infectious diseases, have a promising vaccine candidate. They have developed a replication-competent vaccine against Lassa virus based on recombinant vesicular stomatitis virus vectors expressing the Lassa virus glycoprotein. After a single intramuscular injection, test primates have survived lethal challenge, while showing no clinical symptoms.[1]
References
- ↑ Geisbert TW, Jones S, Fritz EA; et al. (2005). "Development of a new vaccine for the prevention of Lassa fever". PLoS Med. 2 (6): e183. doi:10.1371/journal.pmed.0020183. PMID 15971954.